This article is more than 5 years old. Information may no longer be current.
Interim results of INJECT study show real-world Jetrea experience
Click Here to Manage Email Alerts
DENVER — The long-term effects of Jetrea may be as safe and effective as those seen in registration trials, according to a presentation here.
In a poster presented at the Association for Research in Vision and Ophthalmology annual meeting, Peter Stalmans, MD, PhD, and colleagues discussed the non-interventional, multicenter, prospective INJECT study of 105 patients with vitreomacular traction (VMT) treated with Jetrea (ocriplasmin, ThromboGenics).
“The main goal was to see the real-world experience,” Stalmans told Ocular Surgery News. “Any treatments with ocriplasmin, we’d like to see who you treated, why you treated and then follow them over a period of 1 year.”
Interim analysis included baseline OCT data and at least 28 days of follow-up.
Of the 105 patients, 64 had VMT only and 41 had VMT plus macular hole.
Ocriplasmin was ineffective in eight patients; seven patients had vitreous floaters, seven patients had photopsia, and five patients had reduced visual acuity.
Twelve months after the last patient enters the trial, “we hope to have the clinical study report and be able to have a better understanding of the study,” Stalmans said. “Basically, this is a real-world analysis of what doctors do when they treat a patient with ocriplasmin. We want to garner what types of patients they are treating, and maybe get some subset analyses related to that when it’s all said and done.” - by Kristie L. Kahl
Disclosure: Stalmans reports he is a consultant for Alcon Laboratories.